ARCA biopharma, Inc. Logo

ARCA biopharma, Inc.

ABIO

(1.8)
Stock Price

3,40 USD

-10.41% ROA

-11.29% ROE

-5.79x PER

Market Cap.

23.631.123,00 USD

0.59% DER

0% Yield

0% NPM

ARCA biopharma, Inc. Stock Analysis

ARCA biopharma, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

ARCA biopharma, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.69x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a low debt to equity ratio (1%), which means it has a small amount of debt compared to the ownership it holds

3 Revenue Growth

Over the past three years, this company's revenue has consistently grown, demonstrating a positive financial trend that makes it an appealing choice.

4 Net Profit Growth

The net profit of this company has shown steady growth over the past three years, highlighting its positive financial trajectory and making it an appealing choice for potential investors.

5 Graham Number

The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.

6 ROE

Negative ROE (-10.23%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

7 ROA

The stock's ROA (-10.41%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

8 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

ARCA biopharma, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

ARCA biopharma, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

ARCA biopharma, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

ARCA biopharma, Inc. Revenue
Year Revenue Growth
1996 400.000
1997 6.200.000 93.55%
1998 9.600.000 35.42%
1999 6.400.000 -50%
2000 15.604.000 58.98%
2001 24.590.000 36.54%
2002 26.433.000 6.97%
2003 2.290.000 -1054.28%
2004 195.000 -1074.36%
2005 545.000 64.22%
2006 3.888.000 85.98%
2007 46.861.000 91.7%
2008 15.251.000 -207.27%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

ARCA biopharma, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1996 3.700.000
1997 9.400.000 60.64%
1998 19.200.000 51.04%
1999 18.200.000 -5.49%
2000 29.018.000 37.28%
2001 46.506.000 37.6%
2002 50.157.000 7.28%
2003 33.084.000 -51.61%
2004 39.970.000 17.23%
2005 57.778.000 30.82%
2006 89.370.000 35.35%
2007 42.654.000 -109.52%
2008 27.764.000 -53.63%
2009 10.010.000 -177.36%
2010 3.106.000 -222.28%
2011 2.315.000 -34.17%
2012 1.092.000 -112%
2013 2.928.000 62.7%
2014 5.625.000 47.95%
2015 7.063.000 20.36%
2016 12.348.000 42.8%
2017 14.076.000 12.28%
2018 4.239.000 -232.06%
2019 1.833.000 -131.26%
2020 4.992.000 63.28%
2021 13.832.000 63.91%
2022 4.749.000 -191.26%
2023 1.288.000 -268.71%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

ARCA biopharma, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1996 1.700.000
1997 4.900.000 65.31%
1998 9.500.000 48.42%
1999 8.100.000 -17.28%
2000 9.315.000 13.04%
2001 13.452.000 30.75%
2002 18.144.000 25.86%
2003 17.223.000 -5.35%
2004 8.702.000 -97.92%
2005 15.801.000 44.93%
2006 30.632.000 48.42%
2007 20.762.000 -47.54%
2008 14.939.000 -38.98%
2009 12.840.000 -16.35%
2010 6.069.000 -111.57%
2011 5.046.000 -20.27%
2012 3.227.000 -56.37%
2013 4.012.000 19.57%
2014 4.068.000 1.38%
2015 4.392.000 7.38%
2016 4.265.000 -2.98%
2017 4.636.000 8%
2018 3.879.000 -19.52%
2019 3.981.000 2.56%
2020 4.774.000 16.61%
2021 5.503.000 13.25%
2022 5.847.000 5.88%
2023 6.460.000 9.49%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

ARCA biopharma, Inc. EBITDA
Year EBITDA Growth
1996 -4.900.000
1997 -8.600.000 43.02%
1998 -19.800.000 56.57%
1999 -16.900.000 -17.16%
2000 -19.605.000 13.8%
2001 -29.439.000 33.4%
2002 -33.539.000 12.22%
2003 -42.488.000 21.06%
2004 -44.360.000 4.22%
2005 -70.639.000 37.2%
2006 -112.932.000 37.45%
2007 -11.876.000 -850.93%
2008 -17.584.000 32.46%
2009 -22.176.000 20.71%
2010 -8.074.000 -174.66%
2011 -6.757.000 -19.49%
2012 -4.274.000 -58.1%
2013 -6.909.000 38.14%
2014 -9.674.000 28.58%
2015 -11.422.000 15.3%
2016 -16.124.000 29.16%
2017 -18.545.000 13.05%
2018 -7.934.000 -133.74%
2019 -5.553.000 -42.88%
2020 -9.738.000 42.98%
2021 -19.322.000 49.6%
2022 -10.596.000 -82.35%
2023 -7.748.000 -36.76%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

ARCA biopharma, Inc. Gross Profit
Year Gross Profit Growth
1996 800.000
1997 7.400.000 89.19%
1998 11.600.000 36.21%
1999 9.400.000 -23.4%
2000 18.728.000 49.81%
2001 24.590.000 23.84%
2002 26.433.000 6.97%
2003 2.290.000 -1054.28%
2004 195.000 -1074.36%
2005 545.000 64.22%
2006 3.888.000 85.98%
2007 46.861.000 91.7%
2008 15.251.000 -207.27%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

ARCA biopharma, Inc. Net Profit
Year Net Profit Growth
1996 -4.800.000
1997 -6.500.000 26.15%
1998 -16.400.000 60.37%
1999 -18.500.000 11.35%
2000 -22.253.000 16.87%
2001 -36.472.000 38.99%
2002 -44.978.000 18.91%
2003 -50.187.000 10.38%
2004 -52.489.000 4.39%
2005 -71.611.000 26.7%
2006 -130.553.000 45.15%
2007 -12.301.000 -961.32%
2008 -29.923.000 58.89%
2009 -9.138.000 -227.46%
2010 -8.420.000 -8.53%
2011 -5.364.000 -56.97%
2012 -4.320.000 -24.17%
2013 -6.939.000 37.74%
2014 -9.689.000 28.38%
2015 -11.445.000 15.34%
2016 -16.463.000 30.48%
2017 -18.490.000 10.96%
2018 -7.931.000 -133.14%
2019 -5.482.000 -44.67%
2020 -9.738.000 43.71%
2021 -19.231.000 49.36%
2022 -9.256.000 -107.77%
2023 -5.696.000 -62.5%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

ARCA biopharma, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1996 -17.143
1997 -23.214 26.16%
1998 -57.544 59.66%
1999 -64.236 10.42%
2000 -73.685 12.82%
2001 -85.816 14.14%
2002 -88.365 2.88%
2003 -36.054 -145.1%
2004 -25.717 -40.19%
2005 -26.231 1.96%
2006 -38.375 31.65%
2007 -3.488 -1000.52%
2008 -29.863 88.32%
2009 -974 -2966.02%
2010 -748 -30.21%
2011 -404 -85.61%
2012 -245 -65.16%
2013 -101 -141.58%
2014 -60 -71.19%
2015 -33 -84.38%
2016 -33 0%
2017 -32 -3.23%
2018 -10 -210%
2019 -4 -150%
2020 -2 -100%
2021 -1 -100%
2022 -1 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

ARCA biopharma, Inc. Free Cashflow
Year Free Cashflow Growth
1996 -5.200.000
1997 -11.200.000 53.57%
1998 -16.300.000 31.29%
1999 -17.400.000 6.32%
2000 -29.256.000 40.53%
2001 -34.120.000 14.26%
2002 -33.382.000 -2.21%
2003 -45.386.000 26.45%
2004 -50.776.000 10.62%
2005 -61.605.000 17.58%
2006 -39.502.000 -55.95%
2007 -46.339.000 14.75%
2008 -46.730.000 0.84%
2009 -41.911.000 -11.5%
2010 -8.328.000 -403.25%
2011 -6.978.000 -19.35%
2012 -4.078.000 -71.11%
2013 -5.320.000 23.35%
2014 -9.425.000 43.55%
2015 -10.545.000 10.62%
2016 -14.999.000 29.7%
2017 -17.475.000 14.17%
2018 -8.248.000 -111.87%
2019 -4.805.000 -71.65%
2020 -7.744.000 37.95%
2021 -18.805.000 58.82%
2022 -10.914.000 -72.3%
2023 -1.669.000 -553.92%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

ARCA biopharma, Inc. Operating Cashflow
Year Operating Cashflow Growth
1996 -4.300.000
1997 -8.100.000 46.91%
1998 -11.700.000 30.77%
1999 -13.000.000 10%
2000 -20.987.000 38.06%
2001 -21.538.000 2.56%
2002 -31.319.000 31.23%
2003 -45.066.000 30.5%
2004 -50.112.000 10.07%
2005 -59.035.000 15.11%
2006 -37.060.000 -59.3%
2007 -45.958.000 19.36%
2008 -46.508.000 1.18%
2009 -41.726.000 -11.46%
2010 -8.324.000 -401.27%
2011 -6.959.000 -19.61%
2012 -4.078.000 -70.65%
2013 -5.288.000 22.88%
2014 -9.406.000 43.78%
2015 -10.534.000 10.71%
2016 -14.987.000 29.71%
2017 -17.472.000 14.22%
2018 -8.244.000 -111.94%
2019 -4.801.000 -71.71%
2020 -7.725.000 37.85%
2021 -18.762.000 58.83%
2022 -10.912.000 -71.94%
2023 -1.669.000 -553.8%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

ARCA biopharma, Inc. Capital Expenditure
Year Capital Expenditure Growth
1996 900.000
1997 3.100.000 70.97%
1998 4.600.000 32.61%
1999 4.400.000 -4.55%
2000 8.269.000 46.79%
2001 12.582.000 34.28%
2002 2.063.000 -509.89%
2003 320.000 -544.69%
2004 664.000 51.81%
2005 2.570.000 74.16%
2006 2.442.000 -5.24%
2007 381.000 -540.94%
2008 222.000 -71.62%
2009 185.000 -20%
2010 4.000 -4525%
2011 19.000 78.95%
2012 0 0%
2013 32.000 100%
2014 19.000 -68.42%
2015 11.000 -72.73%
2016 12.000 8.33%
2017 3.000 -300%
2018 4.000 25%
2019 4.000 0%
2020 19.000 78.95%
2021 43.000 55.81%
2022 2.000 -2050%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

ARCA biopharma, Inc. Equity
Year Equity Growth
1996 7.400.000
1997 62.900.000 88.24%
1998 47.600.000 -32.14%
1999 29.200.000 -63.01%
2000 8.362.000 -249.2%
2001 15.421.000 45.78%
2002 -4.564.000 437.88%
2003 22.701.000 120.1%
2004 45.589.000 50.21%
2005 56.764.000 19.69%
2006 69.843.000 18.73%
2007 67.659.000 -3.23%
2008 42.508.000 -59.17%
2009 7.412.000 -473.5%
2010 6.771.000 -9.47%
2011 5.732.000 -18.13%
2012 2.907.000 -97.18%
2013 15.581.000 81.34%
2014 14.741.000 -5.7%
2015 38.070.000 61.28%
2016 22.194.000 -71.53%
2017 10.275.000 -116%
2018 6.032.000 -70.34%
2019 7.610.000 20.74%
2020 46.521.000 83.64%
2021 51.043.000 8.86%
2022 41.673.000 -22.48%
2023 37.968.000 -9.76%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

ARCA biopharma, Inc. Assets
Year Assets Growth
1996 9.400.000
1997 67.000.000 85.97%
1998 57.900.000 -15.72%
1999 45.400.000 -27.53%
2000 21.288.000 -113.27%
2001 39.904.000 46.65%
2002 27.072.000 -47.4%
2003 57.809.000 53.17%
2004 79.264.000 27.07%
2005 108.046.000 26.64%
2006 184.405.000 41.41%
2007 120.683.000 -52.8%
2008 66.045.000 -82.73%
2009 9.372.000 -604.71%
2010 8.156.000 -14.91%
2011 6.502.000 -25.44%
2012 3.212.000 -102.43%
2013 17.084.000 81.2%
2014 16.132.000 -5.9%
2015 39.574.000 59.24%
2016 24.629.000 -60.68%
2017 12.365.000 -99.18%
2018 6.825.000 -81.17%
2019 8.536.000 20.04%
2020 50.429.000 83.07%
2021 54.924.000 8.18%
2022 43.085.000 -27.48%
2023 39.184.000 -9.96%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

ARCA biopharma, Inc. Liabilities
Year Liabilities Growth
1996 2.000.000
1997 4.100.000 51.22%
1998 10.300.000 60.19%
1999 16.200.000 36.42%
2000 12.926.000 -25.33%
2001 24.371.000 46.96%
2002 31.636.000 22.96%
2003 35.108.000 9.89%
2004 33.675.000 -4.26%
2005 51.282.000 34.33%
2006 114.562.000 55.24%
2007 53.024.000 -116.06%
2008 23.537.000 -125.28%
2009 1.960.000 -1100.87%
2010 1.385.000 -41.52%
2011 770.000 -79.87%
2012 305.000 -152.46%
2013 1.503.000 79.71%
2014 1.391.000 -8.05%
2015 1.504.000 7.51%
2016 2.435.000 38.23%
2017 2.090.000 -16.51%
2018 793.000 -163.56%
2019 926.000 14.36%
2020 3.908.000 76.31%
2021 3.881.000 -0.7%
2022 1.412.000 -174.86%
2023 1.216.000 -16.12%

ARCA biopharma, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.28
Price to Earning Ratio
-5.79x
Price To Sales Ratio
0x
POCF Ratio
-4.33
PFCF Ratio
-4.33
Price to Book Ratio
0.62
EV to Sales
0
EV Over EBITDA
2.03
EV to Operating CashFlow
2.68
EV to FreeCashFlow
2.68
Earnings Yield
-0.17
FreeCashFlow Yield
-0.23
Market Cap
0,02 Bil.
Enterprise Value
-0,01 Bil.
Graham Number
4.1
Graham NetNet
2.59

Income Statement Metrics

Net Income per Share
-0.28
Income Quality
1.01
ROE
-0.1
Return On Assets
-0.12
Return On Capital Employed
-0.2
Net Income per EBT
0.82
EBT Per Ebit
0.73
Ebit per Revenue
0
Effective Tax Rate
0.19

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.38
Free CashFlow per Share
-0.38
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.14
Return on Tangible Assets
-0.1
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
2,67
Book Value per Share
2,63
Tangible Book Value per Share
2.63
Shareholders Equity per Share
2.63
Interest Debt per Share
0.01
Debt to Equity
0.01
Debt to Assets
0.01
Net Debt to EBITDA
5.32
Current Ratio
39.21
Tangible Asset Value
0,04 Bil.
Net Current Asset Value
0,04 Bil.
Invested Capital
0.01
Working Capital
0,04 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

ARCA biopharma, Inc. Dividends
Year Dividends Growth

ARCA biopharma, Inc. Profile

About ARCA biopharma, Inc.

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.

CEO
Dr. Michael R. Bristow M.D., P
Employee
4
Address
10170 Church Ranch Way
Westminster, 80021

ARCA biopharma, Inc. Executives & BODs

ARCA biopharma, Inc. Executives & BODs
# Name Age
1 Mr. Thomas A. Keuer
Chief Operating Officer
70
2 Dr. Michael R. Bristow M.D., Ph.D.
Co-Founder, President, Chief Executive Officer & Director
70
3 Mr. C. Jeffrey Dekker CPA
Chief Financial Officer, Treasurer & Company Secretary
70

ARCA biopharma, Inc. Competitors